Nowak P, Jørgensen K, Rossi M. "Method for the Synthesis of (5Z,13E)-9alpha,11alpha-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid
15-Keto-PGF2a
15-Keto-PGF2alpha
15-Keto-prostaglandin F2a
15-Keto-prostaglandin F2alpha
15-Ketoprostaglandin F2alpha
15-oxoprostaglandin F2alpha
35850-13-6
CHEBI:28442" [P]. European Patent, EP 3234940 A1, 2017-03-15.
Hughes D C, Williams B T, Klinger H. "A Process for Preparing High-Purity (5Z,13E)-9alpha,11alpha-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid
15-Keto-PGF2a
15-Keto-PGF2alpha
15-Keto-prostaglandin F2a
15-Keto-prostaglandin F2alpha
15-Ketoprostaglandin F2alpha
15-oxoprostaglandin F2alpha
35850-13-6
CHEBI:28442" [P]. US Patent, US 10032098 B2, 2017-05-14.
参考文献 Literature
Lee J H, Choi Y S. "Development and Validation of an LC-MS/MS Method for the Determination of 15-keto PGF2α in Pharmaceutical Formulations". J. Pharm. Biomed. Anal., 2016, 2190, (12), 9784-9799.
Wang L, Li J, Zhang H. "A Stability-Indicating HPLC Method for the Separation and Quantification of 15-keto PGF2α as an Impurity". Anal. Methods, 2022, 2158, 6036-6057.
Kim S H, Park J Y. "Identification and Structural Characterization of a Novel Degradation Product of (5Z,13E)-9alpha,11alpha-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid
15-Keto-PGF2a
15-Keto-PGF2alpha
15-Keto-prostaglandin F2a
15-Keto-prostaglandin F2alpha
15-Ketoprostaglandin F2alpha
15-oxoprostaglandin F2alpha
35850-13-6
CHEBI:28442 Using HRMS and NMR". J. Chromatogr. A, 2021, 1568, (12), 3034-3051.